Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm PR Newswire STOCKHOLM, Sept. 16, 2024 STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas...
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei PR Newswire STOCKHOLM, Sept. 3, 2024 STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Calliditas Interim Report January to June 2024 PR Newswire STOCKHOLM, Aug. 13, 2024 STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) : April to...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
Invitation to the presentation of Calliditas´s interim report January - June 2024 PR Newswire STOCKHOLM, Aug. 5, 2024 STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the...
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
